Only 493 people across eight small trials. The two with the most weight loss, on semaglutide and high-dose liraglutide, both reported lower spine and hip bone density.
Recap by typeshit. Full story at BIOENGINEER.
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
Hanmi's GLP-1 drug epeglenatide goes on sale in Korea later this month. Heo, Ko Ji-yong's ex-wife, says she took part in its trial as a professor.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
Loading…